Cell surface differentiation antigens of the malignant T cell in Sezary syndrome and mycosis fungoides

The Journal of Clinical Investigation
B F HaynesA S Fauci

Abstract

Using a panel of monoclonal antibodies and rabbit heteroantisera, we have studied the cell surface markers of peripheral blood (PB) Sezary cells from six patients with mycosis fungoides or Sezary syndrome, disease grouped within the spectrum of cutaneous T cell lymphomas (CTCL). Furthermore, we have studied two cell lines (Hut 78 and Hut 102) derived from malignant Sezary T cells from CTCL patients. The monoclonal antibody 3A1 defines a major human PB T cell subset (85% of PB T cells) while the antigen defined by the monoclonal antibody 4F2 is present on a subset (70%) of activated PB T cells and on circulating PB monocytes. In contrast to normal subjects in whom 60-70% of circulating PB mononuclear cells were 3A1(+) T cells, PB mononuclear cells from six CTCL patients studied had an average of only 10.6+/-3.2% 3A1(+) T cells. Whereas 85% of E-rosette positive cells from normal individuals were 3A1(+), virtually all E-rosette positive T cells from the Sezary patients were 3A1(-). Two patients with high numbers of circulating Sezary T cells had both aneuploid and diploid PB T cell populations present; after separation of PB T cells into 3A1(+) and 3A1(-) cell suspensions, all 3A1(-) cells were found to be aneuploid. In contrast ...Continue Reading

References

Dec 1, 1976·The Journal of Clinical Investigation·S BroderT A Waldmann
Sep 1, 1977·The New England Journal of Medicine·J A DonlonR C Braylan
Nov 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·B F HaynesA S Fauci
Apr 1, 1976·Proceedings of the National Academy of Sciences of the United States of America·S F SchlossmanJ L Strominger
Aug 16, 1973·The New England Journal of Medicine·J C BrouetM Seligmann
Dec 1, 1970·Annals of Internal Medicine·V T DevitaP P Carbone
May 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·B F HaynesA S Fauci
Jun 1, 1980·The Journal of Clinical Investigation·P A BunnA F Gazdar
Dec 5, 1964·Nature·P I TERASAKI, J D MCCLELLAND

❮ Previous
Next ❯

Citations

Nov 2, 1984·Klinische Wochenschrift·H HuberH Stein
Aug 1, 1984·Cancer Genetics and Cytogenetics·V Brito-BabapulleD Catovsky
Jul 1, 1983·The Journal of Clinical Investigation·R I FoxF V Howell
Mar 1, 1985·The Journal of Clinical Investigation·C MorimotoS F Schlossman
Apr 14, 2012·Journal of Cell Science·Joseph M Cantor, Mark H Ginsberg
Aug 2, 2018·Journal of Cellular Physiology·Saeed Mohammadian HaftcheshmehAmirhossein Sahebkar
Jan 1, 1981·Immunological Reviews·B F Haynes
Nov 1, 1983·Scandinavian Journal of Immunology·C Farnarier-SeidelR Depieds
Oct 31, 1996·Annals of the New York Academy of Sciences·A H RookG Trinchieri
Jun 1, 1992·Arthritis and Rheumatism·A I LazarovitsJ Karsh
Jun 15, 1984·International Journal of Cancer. Journal International Du Cancer·M F GreavesM Reitz
Apr 15, 1988·International Journal of Cancer. Journal International Du Cancer·E M SchneiderP Wernet
May 1, 1985·Scandinavian Journal of Haematology·E RalfkiaerK Thomsen
Sep 20, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Melissa A ByersCharlotte M Vines
Feb 1, 1985·Scandinavian Journal of Haematology·A BerrebiE Nir
Nov 5, 1999·Clinical and Diagnostic Laboratory Immunology·J T AbramsB J Balin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.